Immo-bile-izing CD8+ T cell anti-tumor immunity

Scott A. Read; Golo Ahlenstiel

doi:10.1016/j.immuni.2025.02.015

Immo-bile-izing CD8⁺ T cell anti-tumor immunity

Scott A. Read, Golo Ahlenstiel

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Hepatocellular carcinoma is poorly responsive to immune checkpoint blockade. In a recent issue of Science, Varanasi et al. reveal how bile acids dampen anti-tumor CD8⁺ T cell responses in the liver, contributing to cancer progression and poor immunotherapy outcomes.

Original language	English
Pages (from-to)	532-534
Number of pages	3
Journal	Immunity
Volume	58
Issue number	3
DOIs	https://doi.org/10.1016/j.immuni.2025.02.015
Publication status	Published - 11 Mar 2025

Bibliographical note

Publisher Copyright:
© 2025 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.immuni.2025.02.015

Cite this

@article{2ce9d5f35579438cb3f4a6d5c02533e9,

title = "Immo-bile-izing CD8+ T cell anti-tumor immunity",

abstract = "Hepatocellular carcinoma is poorly responsive to immune checkpoint blockade. In a recent issue of Science, Varanasi et al. reveal how bile acids dampen anti-tumor CD8+ T cell responses in the liver, contributing to cancer progression and poor immunotherapy outcomes.",

author = "Read, {Scott A.} and Golo Ahlenstiel",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc.",

year = "2025",

month = mar,

day = "11",

doi = "10.1016/j.immuni.2025.02.015",

language = "English",

volume = "58",

pages = "532--534",

journal = "Immunity",

issn = "1074-7613",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Immo-bile-izing CD8+ T cell anti-tumor immunity

AU - Read, Scott A.

AU - Ahlenstiel, Golo

PY - 2025/3/11

Y1 - 2025/3/11

N2 - Hepatocellular carcinoma is poorly responsive to immune checkpoint blockade. In a recent issue of Science, Varanasi et al. reveal how bile acids dampen anti-tumor CD8+ T cell responses in the liver, contributing to cancer progression and poor immunotherapy outcomes.

AB - Hepatocellular carcinoma is poorly responsive to immune checkpoint blockade. In a recent issue of Science, Varanasi et al. reveal how bile acids dampen anti-tumor CD8+ T cell responses in the liver, contributing to cancer progression and poor immunotherapy outcomes.

UR - http://www.scopus.com/inward/record.url?scp=86000368362&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2025.02.015

DO - 10.1016/j.immuni.2025.02.015

M3 - Article

C2 - 40073845

AN - SCOPUS:86000368362

SN - 1074-7613

VL - 58

SP - 532

EP - 534

JO - Immunity

JF - Immunity

IS - 3

ER -